Why Are Timber Pharmaceuticals Shares Trading Higher Today

  • The FDA has granted dermal carcinogenicity (CARC) waiver for Timber Pharmaceuticals Inc's TMBR TMB-001, a topical isotretinoin formulated using the company's patented IPEG delivery system. 
  • The positive opinion is based on the results of a 39-week repeat dose dermal toxicity study that demonstrated no evidence of skin or organ carcinogenicity from chronic applications of TMB-001 in rodents.
  • The move allows the company to forgo a 2-year dermal rodent carcinogenicity study.
  • "The CARC waiver is important because we can avoid a costly and lengthy non-clinical study, which we believe will allow us to push ahead with our TMB-001 program as quickly and efficiently as possible. We have reached 70% enrollment in our pivotal Phase 3 ASCEND study and are working to open the final sites in Italy this month."
  • TMB-001 is currently being investigated in the Phase 3 ASCEND study for moderate to severe subtypes of congenital ichthyosis, including lamellar ichthyosis and X-linked ichthyosis that affect about 80,000 people in the U.S.
  • In 2018, the FDA awarded an Orphan Products Grant to support clinical trials evaluating TMB-001, including the Phase 3 ASCEND study. 
  • Timber has also received both Breakthrough Therapy Designation and Fast Track Status from the FDA for TMB-001.
  • Price Action: TMBR shares are up 87.90% at $2.80 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!